NEW YORK (GenomeWeb) – A gene expression-based classification signature originally developed for distinguishing luminal and basal breast cancer cases is showing promise classifying prostate cancer cases in ways that help predict response to post-operative androgen deprivation therapy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.